Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group. Ann Intern Med, 125(4), 270-9. presented at the 1996 Aug 15. doi:10.7326/0003-4819-125-4-199608150-00003. (1996).
Safety profile of phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation Group. AIDS Res Hum Retroviruses, 13(14), 1163-77. presented at the 1997 Sep 20. doi:10.1089/aid.1997.13.1163. (1997).
Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection Group. J Infect Dis, 177(2), 310-9. presented at the 1998 Feb. doi:10.1086/514209. (1998).
Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. J Infect Dis, 177(5), 1230-46. presented at the 1998 May. doi:10.1086/515288. (1998).
A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers. J Infect Dis, 180(2), 290-8. presented at the 1999 Aug. doi:10.1086/314895. (1999).
A phase II study of two HIV type 1 envelope vaccines, comparing their immunogenicity in populations at risk for acquiring HIV type 1 infection. AIDS Vaccine Evaluation Group. AIDS Res Hum Retroviruses, 16(9), 907-19. presented at the 2000 Jun 10. doi:10.1089/08892220050042846. (2000).
A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine, 29(2), 304-13. presented at the 2010 Dec 16. doi:10.1016/j.vaccine.2010.10.037. (2010).